Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.32M | $3.81M | $5.69M | $10.3M | $8.56M | $10.2M | $9.97M | $14.2M | $14.2M | $18.8M |
| Revenue growth | — | 64.2% | 49.3% | 81.7% | -17.2% | 19.3% | -2.4% | 42.7% | -0.5% | 32.7% |
| Gross profit | $1.29M | $2.29M | $3.20M | $6.08M | $4.91M | $5.63M | $4.73M | $8.40M | $8.72M | $11.6M |
| Gross margin | 55.8% | 60.2% | 56.3% | 58.9% | 57.4% | 55.1% | 47.4% | 59.0% | 61.6% | 61.9% |
| Operating income | -$2.87M | -$2.23M | -$3.02M | -$3.15M | -$4.28M | -$3.25M | -$4.33M | -$1.59M | $6.00K | $1.15M |
| Operating margin | -123.7% | -58.4% | -53.0% | -30.5% | -49.9% | -31.8% | -43.5% | -11.2% | 0.0% | 6.1% |
| Net income | -$3.03M | -$809K | -$3.40M | -$3.18M | -$4.53M | -$3.87M | -$7.11M | -$1.57M | $74.0K | $1.19M |
| Net margin | -130.7% | -21.2% | -59.8% | -30.8% | -52.9% | -37.8% | -71.2% | -11.1% | 0.5% | 6.4% |
| EPS (diluted) | -$0.06 | -$0.02 | -$0.50 | -$0.45 | -$0.52 | -$0.41 | -$0.73 | -$0.15 | $0.01 | $0.11 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.11M | -$77.0K | -$3.66M | -$2.28M | -$6.90M | -$1.42M | -$3.23M | $827K | -$492K | $1.65M |
| Capital expenditures | $45.0K | — | — | $14.0K | $239K | $36.0K | $137K | $75.0K | $55.0K | — |
| Free cash flow | -$2.16M | — | — | -$2.29M | -$7.14M | -$1.45M | -$3.37M | $752K | -$547K | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | — | $4.17M | $8.25M | $6.97M | $3.63M | $4.31M | $3.76M | $5.40M |
| Total assets | $2.68M | $4.98M | $10.6M | $11.6M | $18.5M | $17.6M | $11.0M | $11.9M | $11.2M | $13.6M |
| Total liabilities | $2.01M | $3.03M | $3.76M | $3.94M | $2.94M | $2.90M | $2.12M | $3.50M | $2.63M | $3.44M |
| Long-term debt | — | — | $1.04M | $824K | $593K | $343K | $71.0K | — | — | — |
| Shareholders' equity | $667K | $1.95M | $6.80M | $7.69M | $15.6M | $14.7M | $8.88M | $8.36M | $8.59M | $10.2M |
| Retained earnings | -$120M | -$121M | -$124M | -$127M | -$132M | -$136M | -$143M | -$144M | -$144M | -$143M |
| Shares (wtd avg diluted) | 49.8M | 55.3M | 7.18M | 8.06M | 9.87M | 10.0M | 10.3M | 10.4M | 10.6M | 11.0M |
Every figure is extracted from NEPHROS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.